Patent: 8,394,765

Summary for Patent: 8,394,765

Title:	Methods of treating obesity with two different anti-obesity agents
Abstract:	Methods for treating obesity or obesity related disorders are disclosed. These methods include the use of anti-obesity agents directed to the forebrain in combination with anti-obesity agents directed to the hindbrain.
Inventor(s):	Roth; Jonathan D. (San Diego, CA), Anderson; Christen M. (Encinitas, CA), Baron; Alain D. (San Diego, CA)
Assignee:	Amylin Pharmaceuticals LLC (San Diego, CA) AstraZeneca Pharmaceuticals LP (Wilmington, DE)
Application Number:	11/940,317
Patent Claims:	see list of patent claims

United States Patent 8,394,765 (Pramlintide + Metreleptin) Claims, Claim Scope, and US Patent Landscape for Anti-Obesity Combination in Leptin-Resistant Subjects

Executive summary: US Patent 8,394,765 claims methods of treating obesity or reducing body weight in leptin-resistant subjects using peripheral administration of two anti-obesity agents: pramlintide plus metreleptin, with dependent claim emphasis on synergy/greater-than-monotherapy weight loss, co-administration timing (same time), and mixing. The patent is framed as a combination regimen with broad subject-condition coverage and multiple claim “hooks” that can support design-around resistance in method-of-treatment litigation, but the claim set is still vulnerable on standard grounds: prior art obviousness for combining well-known weight-loss pharmacologies; lack of clear, claim-limiting evidence of synergy for the specific leptin-resistant population; and route/dosing/formulation ambiguity that can widen or, depending on prosecution history, narrow infringement reach. The most actionable landscape question for challengers and licensees is whether there are earlier US patents or published applications tying pramlintide and metreleptin together (or teaching substituting one for weight-loss), and whether regulatory/IP status supports enforcement leverage.

What are the key independent claim elements in US 8,394,765 (pramlintide + metreleptin obesity treatment)?

Featured snippet answer: The independent claim core is a method that requires (i) an obese leptin-resistant subject, (ii) peripheral administration of two anti-obesity agents where one is pramlintide and the other is metreleptin, and (iii) a therapeutically effective amount that reduces body weight, treating obesity.

Claim 1 and Claim 2 (treating obesity vs reducing body weight)

Both independent claim types are structurally similar:

• Patient phenotype: “obese leptin resistant” subject
• Administration: “peripherally administering therapeutically effective amounts of two different anti-obesity agents”
• Drug identity:
  • one anti-obesity agent is pramlintide
  • one anti-obesity agent is metreleptin
• Outcome: “wherein the subject reduces body weight, thereby treating the obesity” (Claim 1) or “wherein the anti-obesity agents are administered in amounts effective to reduce body weight” (Claim 2)

Scope consequence: The claims are not limited to a specific dose, schedule, duration, or exact formulation container. That can expand infringement risk for any regimen meeting the phenotypic and drug identity requirements.

Claim 19/20 (consisting essentially of)

These track the same regimen concept but add a “consisting essentially of” limitation:

• Same two actives (pramlintide + metreleptin)
• “consisting essentially of” can admit minor additional components (e.g., acceptable excipients) while excluding additional therapeutic agents that materially affect the claimed combination.

Scope consequence: This is a litigation lever for plaintiffs to argue that typical ancillary meds or lifestyle support do not take the regimen outside the claims, but it is also a lever for defendants to argue that additional anti-obesity agents or substantial adjunct pharmacology materially alters the method.

Claim 24 (formulation route)

Claim 24 shifts from two separate “agents” toward a peripheral administration of two pharmaceutical formulations, one containing pramlintide and one containing metreleptin.

Scope consequence: It increases relevance to product development and commercial readiness because it anchors infringement around administration of formulations containing each active, not merely “therapeutic agents” in abstract.

Claim 29/30 (formulation with “consisting of” / composition formulation framing)

Claims 29 and 30 use “consisting of” language for the method steps, but still center on peripheral administration of a pramlintide formulation and a metreleptin formulation.

Scope consequence: These claims can narrow the method-step envelope compared to “consisting essentially of,” but in practice they still permit standard excipients and administration mechanics.

---

How narrow or broad are the dependent claims (synergy, same-time dosing, mixing, comorbidities)?

Synergy / greater-than-monotherapy weight loss (Claims 3, 21, 25, 33)

Multiple dependents require:

• an amount of pramlintide and an amount of metreleptin such that
• “a greater amount of weight loss is achieved when pramlintide is administered in combination with metreleptin”
• than the weight loss achieved when either agent is administered alone

Scope consequence: This is the most claim-limiting element besides “leptin resistant” because it imports a comparative performance requirement. In infringement, the plaintiff can use trial data or clinical outcomes from combination arms. In invalidity, defendants can argue that prior art or background teachings already expected/achieved combination benefits, or that the comparative result is not enabled for the full claim breadth.

Litigation pressure point: “Greater amount of weight loss” is conceptually simple but experimentally loaded. It can become a fight over:

• baseline comparators
• statistical significance
• endpoint selection (weight vs percent weight loss)
• time window and titration schedule

Same-time administration (Claims 4, 22, 28)

These dependents specify:

• pramlintide and metreleptin are administered at the same time

Scope consequence: This narrows to concurrent administration. It does not necessarily exclude separated administration by a short interval unless the claim construction treats “same time” strictly. It does create a design-around: stagger dosing.

Mixing together (Claims 5, 23, 27)

These require:

• pramlintide and metreleptin are mixed together

Scope consequence: This is a strong manufacturing/design constraint. If a commercial product uses separate injections or separate infusion bags, defendants can argue non-infringement of the “mixed together” dependents.

Critical note for claim strategy: Mixed-together dependents can still matter because if independent claims do not require mixing, those dependents may not be needed for infringement. But in licensing or settlement, these dependents can be used to press a broader “product” understanding.

Body composition endpoint (Claim 6)

• reduces body fat mass

Scope consequence: Adds an additional measurable outcome. It can widen enforcement if the accused regimen reduces fat mass, but it can also restrict infringement if a sponsor argues only weight (not fat mass) is reduced.

Condition list expansion (Claims 7-14)

Claim 7 adds at least one condition selected from:

• overweight
• diabetes
• insulin-resistance syndrome
• nonalcoholic steatohepatitis (NASH)
• cardiovascular disease
• polycystic ovary syndrome (PCOS)
• metabolic syndrome

Scope consequence: This broadens patient eligibility while tethering to leptin resistance. It also creates extra invalidity routes because metabolic and insulin-related prior art may overlap.

Human and human adult female (Claims 15-16)

• subject is human
• subject is human adult female

Scope consequence: These dependents narrow to specific patient subsets. Many method claims are likely to be asserted broadly under independent claims, with dependents used as “alternative” fallback positions.

Weight-loss thresholds (Claims 17-18)

• reduces body weight by at least 5% (Claim 17)
• reduces by at least 10% (Claim 18)

Scope consequence: Threshold dependents can help plaintiffs because they give quantifiable endpoints. They also help defendants by allowing argument that combination benefit did not reliably reach those thresholds in relevant populations.

---

How is “leptin resistance” used, and why it matters for patent scope and invalidity?

“Obese leptin resistant subject” is a gating limitation across independent and many dependents. Its importance is twofold:

1. Scope gate: It limits the method to a particular patient phenotype. Companies can attempt to avoid infringement by selecting patient strata not characterized as leptin-resistant, or by arguing classification standards are not met.
2. Prior art mapping: It can also restrict which prior art is “closest.” If earlier weight-loss combination references do not identify leptin resistance as a selection criterion, defendants have a more credible obviousness and anticipation argument depending on how “leptin resistant” is construed and whether the references implicitly teach it.

In litigation, construction of “leptin resistant” can become decisive, particularly if “leptin resistance” is operationalized in the specification (e.g., leptin levels, receptor mutations, clinical response measures).

---

What does the pramlintide + metreleptin combination imply for obviousness risk?

Featured snippet answer: The combination claim is vulnerable if earlier US or foreign prior art taught (a) pramlintide as an anti-obesity agent or weight-loss adjunct, and (b) metreleptin or leptin pathway therapies for obesity-related leptin dysfunction, in a way that made combining them a straightforward therapeutic option in leptin-resistant patients.

Common obviousness pathways

• Motivation: Both drugs work through metabolic appetite/weight-control biology. A challenger can argue that using two agents with different weight-relevant mechanisms is routine.
• Reasonable expectation: If prior art reported additive or synergistic weight loss with combination therapies generally, or with one drug plus other metabolic modulators, expectation can be argued.
• Patient tailoring: If metreleptin is described for leptin deficiency/insufficiency and pramlintide targets appetite pathways, then targeting leptin-resistant obesity could be framed as a logical next step.

How the synergy dependents affect obviousness

Even if combination is obvious as a general concept, the dependents requiring “greater amount of weight loss” can provide plaintiffs a wedge: they need to show the combination yields a measurable incremental benefit over monotherapy within the claimed population and dosing context.

But in invalidity, defendants can use prior art combination outcomes or argue that the “greater weight loss” result is inherent or predictable from known mechanisms, or that the claimed comparative improvement is not supported across the full breadth.

---

What is the patent estate strategy: single patent vs broader family?

Without the full bibliographic record (publication numbers, priority filings, and family members), the ability to map the complete US and PCT family is constrained. However, as a matter of claim architecture, US 8,394,765 reads like a combination-method patent with multiple dependents directed to operational implementation (same-time vs mixed; composition-formulation variants; weight thresholds; patient comorbidities).

Practical inference for enforcement: Even if one claim falls due to a claim construction or prior art reference, the structure provides multiple overlapping fallback claims, especially the repeated “synergy” dependents and formulation framing.

---

What infringement theories does US 8,394,765 enable (and how can companies design around)?

Likely plaintiff infringement theories

• Method-of-treatment: A sponsor that markets or practices a regimen matching independent claims can be asserted under method-of-use infringement if the regimen is performed and directed to practitioners/patients.
• Active compliance/labeling alignment: If instructions, physician education, or clinical trial protocols reflect the “peripheral administration” of both actives in leptin-resistant obese subjects, that increases enforcement traction.

Design-around routes

• Stagger dosing to avoid “same time” dependents (claims 4/22/28).
• Avoid mixing in a single admixture to avoid “mixed together” dependents (claims 5/23/27).
• Select non-leptin-resistant populations or avoid a defensible characterization standard for “leptin resistant” to reduce engagement of independent claim limitations.
• Break synergy positioning by ensuring clinical outcomes do not satisfy the “greater weight loss” comparative requirement tied to specific dosing relationships (if that becomes an essential element in a particular claim assert strategy).
• Use different active anti-obesity agents for adjunct therapy to escape any “two different anti-obesity agents” requirement.

---

What to expect in FDA, Orange Book, and regulatory alignment for enforcement leverage?

This patent is a method of treating obesity with specific actives. Enforcement leverage typically depends on whether the sponsor can anchor the regimen to an FDA-approved indication, and whether the accused regimen is practiced under labeling or clinical protocols.

For FDA pathway risk analysis, method patents can still be asserted even if not explicitly tied to a listed indication, but the strongest standing is often where:

• labeling supports patient selection aligning with leptin resistance
• clinical protocols follow the claimed combination or regimen structure
• manufacturing and administration instructions reflect peripheral co-administration concepts

Method claims can also be paired with formulation/composition patents in the broader estate, but the claim set here focuses on method steps rather than, say, drug-product specific release profiles.

---

How strong is the patent’s claim set as a licensing asset?

Featured snippet answer: Strength is driven by (i) the narrow patient phenotype (“obese leptin resistant”), (ii) the specific drug pairing (pramlintide + metreleptin), and (iii) the presence of multiple dependent claims that capture common administration modalities. Weakness is driven by the need for comparative “greater weight loss” to be proven for certain dependents, and by the potential for obviousness arguments combining known weight-loss pharmacologies.

Claim-set positives

• Explicit drug identity reduces overbreadth against unrelated combinations.
• “Peripherally administering” helps exclude purely central delivery concepts, matching expected clinical practice.
• Multiple parallel claim branches for obesity treatment, body weight reduction, and formulation-based framing create multiple infringement hooks.

Claim-set vulnerabilities

• “Leptin resistant” can be a moving target if the specification does not define objective criteria.
• Synergy dependents import evidentiary and experimental specificity.
• Patient condition dependent expansions can broaden obviousness mapping to metabolic disease prior art.

---

What patent litigation risks and Paragraph IV scenarios are plausible?

Method patents like this are often asserted in life-cycle disputes where an accused product provides one or both actives and a sponsor offers a regimen that matches the method steps. Standard generic/biologic entry via FDA pathways can still create litigation risk if the labeling or physician guidance effectively directs the claimed combination in leptin-resistant obese patients.

Paragraph IV is relevant for small molecules and some biologic frameworks, but the key actionable point is whether a defendant seeks to market a regimen or components that enable practicing the method.

---

Comparative landscape: where is the competition most likely to cluster?

Competition will cluster around:

• anti-obesity regimens combining appetite/regulatory peptides
• leptin pathway therapies (metreleptin category) used for obesity-related leptin dysfunction
• adjunct metabolic therapies aiming for weight reduction in insulin-resistant phenotypes

Strategic implication: If competitors pursue a combination in leptin-resistant patients, they face the highest risk of mapping to independent claims. If they pursue non-leptin-resistant obesity or avoid co-administration, risk drops substantially.

---

Key Takeaways

• US 8,394,765 claims peripheral, therapeutically effective combination therapy in obese leptin-resistant subjects using pramlintide + metreleptin to reduce body weight.
• Dependent claims emphasize comparative synergy (“greater weight loss than either alone”), concurrent administration, and mixing together, plus measurable endpoints (fat mass) and quant thresholds (≥5% and ≥10% weight loss).
• The phenotype limitation (“leptin resistant”) is the main scope gate for both infringement and invalidity mapping.
• The most practical design-arounds target (i) timing (avoid same-time), (ii) formulation/administration mechanics (avoid mixing), and (iii) patient selection (avoid a defensible “leptin resistant” classification).
• The strongest licensing position typically rests on the independent claim breadth paired with the synergy dependents as fallback, while the principal vulnerability is the evidentiary and obviousness framing around the comparative weight-loss requirement in the leptin-resistant population.

FAQs

1) What makes the “consisting essentially of” limitation in Claims 19 and 20 material for enforcement?
It can exclude additional therapeutic agents that materially affect the method while allowing excipients and routine components; it becomes central when accused regimens add other anti-obesity pharmacotherapies.

2) Does “mixed together” in Claim 5 require a single combined formulation for infringement?
It reads as a manufacturing/administration constraint, so mixing concepts typically require a combined admixture or product configuration; separate co-injections are a likely non-infringement pathway for those dependents.

3) How do the ≥5% and ≥10% weight-loss dependents interact with evidentiary burdens?
They create quantifiable thresholds that can be tested against clinical endpoints, making them useful in settlement leverage but also potentially contestable if real-world or trial results do not consistently meet the thresholds.

4) Can a competitor avoid infringement by dosing pramlintide and metreleptin at different times?
This targets dependents limited to “same time” (Claims 4/22/28). If independent claims are asserted without that limitation, timing design-arounds may reduce risk only for those dependent claims.

5) What is the most likely invalidity battleground for this patent’s synergy language?
Whether prior art and known combination therapy expectations provide a “greater weight loss” outcome in leptin-resistant obesity, and whether the specification supports the claimed comparative benefit across the full scope.

---

References

1. Claims provided in the prompt (US Patent 8,394,765 claim text).

Details for Patent 8,394,765

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Chiesi Farmaceutici S.p.a.	MYALEPT	metreleptin	For Injection	125390	February 24, 2014	8,394,765	2027-11-14